SCHEMBL14788083

SCHEMBL14788083

CC(=O)Nc1oc2c(c1-c1nc3ccccc3s1)CC(C)(C)NC2(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APEX1 P27695 8/20 0.49
▸ MAPT P10636 3/20 0.46
▸ POLB P06746 2/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ KMT2A Q03164 3/20 0.45
▸ MITF O75030 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ UHRF1 Q96T88 3/20 0.44
▸ KDM4E B2RXH2 4/20 0.43
▸ RAB9A P51151 3/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ USP2 O75604 2/20 0.42
▸ ATM Q13315 1/20 0.42
▸ ADORA1 P30542 1/20 0.42
▸ DYRK1A Q13627 1/20 0.42
▸ MEN1 O00255 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14791461 0.85 APEX1 (0.48) APEX1MAPTPOLBTDP1L3MBTL1
SCHEMBL13833635 0.81 APEX1 (0.62) APEX1MAPTPOLBTDP1L3MBTL1
SCHEMBL13833700 0.77 MAPT (0.55) APEX1MAPTPOLBTDP1L3MBTL1
SCHEMBL13833795 0.73 MAPT (0.55) APEX1MAPTPOLBTDP1L3MBTL1
SCHEMBL13833712 0.70 LMNA (0.55) APEX1MAPTPOLBTDP1L3MBTL1
SCHEMBL14791512 0.69 APEX1 (0.61) APEX1MAPTPOLBTDP1L3MBTL1
SCHEMBL13833661 0.68 APEX1 (0.68) APEX1MAPTPOLBTDP1L3MBTL1
SCHEMBL13832374 0.66 APEX1 (1.00) APEX1POLBKMT2AUHRF1KDM4E
SCHEMBL13833643 0.66 APEX1 (0.69) APEX1MAPTPOLBTDP1L3MBTL1
SCHEMBL14788137 0.66 KDM4E (0.47) APEX1MAPTPOLBTDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. 2013-03-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS HSPA5, PSMG3, VCP APEX1 2669/4885MAPT 221/4885POLB 2314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback